

Guideline Amendment Summary

Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia

Published 2021; Amended 2023

The changes below constitute updates made in the 2023 Amendment:

Section	Document Update
Methodology	The methodology section was updated to note updated search dates and amendment peer review details.
Background	A section was added on “Legacy Technologies”. This included the removal of the TUNA (previous statement 38) and TUMT (previous statement 35) statements from the guideline.
Statement #19	No change to statement. Supporting text updated to include subheadings for clarification.
Statement #20	No change to statement. Combined tolterodine/doxazosin versus combined mirabegron/doxazosin (Elbaz).
Statement #21	Statement updated to align with new statement 22. Supporting text updated with new reference on silodosin 8mg vs. PDE-5 (tadalafil) 5mg (AbdelRazek).
Statement #22	New statement on combination of low dose daily tadalafil 5mg with finasteride.
Statement #33	Previously statement 32. No change to statement. Supporting text updated with new reference on Photoselective Vaporization 180 W (Elshal AM).

Section	Document Update
Statement #36	No statement change. Supporting text was updated with new reference on 60-month data (McVary).
Statement #38	Previously statement 39, no change to statement. Supporting text updated with references on HoLEP (Habib, Higazy, Elshal), ThuLEP (Enikeev, Shaoji), and other enucleation (Samir, Enikeev).
Statement #39	No statement change. Supporting text was updated with new reference on 60-month data (Gilling).
Statement #40	Previously statement 41, statement on PAE was edited to provide clarity of panel intention. Supporting text was also updated to include references (Insausti, Radwan, Pisco).
Statement #41	New statement on temporary implanted prostatic devices (TIPD).
Future Directions	Future Directions were updated to further discuss educational opportunities, therapeutic opportunities, standardization of outcomes, and need for diverse population in research related to BPH.
References	The reference list was updated to reflect document additions and deletions.
Algorithm	The BPH algorithm was updated to reflect all statement changes referenced herein.

Note: Additional editorial changes were made throughout the guideline to align with current AUA guideline criteria and for consistency purposes. These additional changes were not substantial and were not content-related.